Titolo progetto: Class IIa HDACs as therapeutic targets in human diseases: new roles and new selective inhibitors

Programma di finanziamento: PRIN 2017

Responsabile scientifico: prof. Claudio Brancolini

Collaboratori: 

Ruolo del DAME: coordinatore

Descrizione generale:

The project conjugates high quality basic research with a fervent translational approach. The basic research arm will investigate the epigenetic mechanisms implicated in three important diseases that affect the population: stroke, cancer and pain chronification. The translational research arm will identify and optimize new small molecules with therapeutic potential to challenge these diseases.

Focus of the research activities of all team's units is a family of transcriptional repressors: the class IIa HDACs. Different and innovative strategies of screening, exploiting small compounds, bicyclic peptides and virtual approaches, will be applied to identify new class IIa HDACs inhibitors. New and specific domains of these epigenetic regulators will be interrogated as druggable targets.

In parallel, functional studies, using genome-editing techniques will be performed to clarify the contribution of the different class IIa members to stroke, cancer and pain chronification. The genetic signatures and the epigenomes under the influence of class IIa HDACs will be scrutinized in the three disease models. In summary the proposal aims to achieve therapeutic solutions against three important diseases, by targeting class IIa HDACs and thus reversing the pathological status.

Partner del progetto:

Università di Firenze
Università di Roma la Sapienza
Università di Napoli Federico II
Università di Padova
Università di Venezia Ca’Foscari

Date inizio e fine progetto: 01.09.2019 – 28.02.2023

Budget totale del progetto: 148.680,00€

Sito web:

Contatti: claudio.brancolini@uniud.it